glp 1 in australia The rapid rise the use of GLP-1 weight-loss medications in is raising serious concerns. While effective for weight loss and specific chronic disease management, up to 40% of the loss Australia officially entered its GLP-1

Effects on classic cardiovascular risk factors CVOTs on GLP-1RAs Data from the major CVOTs ELIXA, SUSTAIN-6, EXSCEL, HARMONY, PIONEER 6, LEADER, REWIND, and AMPLITUDE-O [53, 54, 56, 59,60,61,62,63] support the overall safety of GLP-1RAs relative to major cardiovascular outcomes

In ongoing trials of Eli Lillys next-generation obesity drug, several participants are running into an issue they never expected: They are losing too much weight

Additionally, GLP-1RA dosage exhibits a dose-dependent effect on cancer risk modulation

At the same time, the entire weight-loss conversation is changing because of GLP-1 medications like Ozempic and Wegovy